HPV Tumor-Status Testing
Testing meets coverage criteria when ALL of the following are satisfied:
ALL of the following
Eligible clinical indication
The individual has oropharyngeal squamous cell carcinoma.
The individual has metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node.
Specified testing method
Testing for high-risk HPV using mRNA expression testing for HPV E6/E7.
Testing for high-risk HPV using immunohistochemistry for p16 expression.
Non-Covered Oral Cancer Screening and Diagnostic Testing
Testing to screen, detect, or diagnose oral cancer does not meet coverage criteria when it involves ANY of the following categories:
ANY of the following testing categories
Salivary biomarker testing, including peptides/proteins, nucleic acids, or metabolites.
Genotyping of HPV, such as OraRisk® HPV.
Gene expression profiling.
Panels that incorporate genetic risk factors with nongenetic biomarkers, such as mRNA CancerDetect™.
Detection of HPV from an oropharyngeal swab, such as the OmniPathology Oropharyngeal HPV PCR Test.
Establishing HPV Tumor Status
Coverage is established for the clinical use of high-risk HPV testing to establish tumor status when ALL of the following apply:
ALL of the following
Cancer diagnosis or presentation
Oropharyngeal squamous cell carcinoma is present.
Metastatic squamous cell carcinoma of unknown primary origin is present in a cervical lymph node.
Testing method
High-risk HPV mRNA expression testing for HPV E6/E7 is performed.
Immunohistochemistry for p16 expression is performed.
Oral Cancer Screening and Detection Tests That Do Not Meet Coverage Criteria
Oral cancer screening and detection testing does not meet coverage criteria when the testing is used for screening, detection, or diagnosis rather than to establish HPV tumor status in an eligible cancer presentation.
Exclusion logic
The testing is intended to screen for, detect, or diagnose oral cancer.
Affected testing category
Salivary biomarker testing, including peptides/proteins, nucleic acids, or metabolites.
HPV genotyping, including OraRisk® HPV.
Gene expression profiling.
Panels combining genetic risk factors with nongenetic biomarkers, including mRNA CancerDetect™.
Coverage is limited to high-risk HPV testing used to establish tumor status in individuals with oropharyngeal squamous cell carcinoma or metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node, when testing uses mRNA expression for HPV E6/E7 or immunohistochemistry for p16 expression. Salivary biomarker testing, HPV genotyping such as OraRisk® HPV, gene expression profiling, and panels combining genetic risk factors with nongenetic biomarkers such as mRNA CancerDetect™ do not meet coverage criteria for screening, detection, or diagnosis of oral cancer. Detection of HPV from an oropharyngeal swab, such as the OmniPathology Oropharyngeal HPV PCR Test, also does not meet coverage criteria.
The OmniPathology oropharyngeal swab test is designed to screen asymptomatic individuals for high-risk HPV in the oropharynx and does not depend on clinical signs, symptoms, or a confirmed tumor. Routine oropharyngeal swab screening in asymptomatic individuals is not recommended in the latest cancer guidelines, including the CAP 2025 guideline, which does not recommend routine screening for oropharyngeal squamous cell carcinoma or HPV-associated head and neck cancers in asymptomatic individuals. Endorsed testing is based on a confirmed or suspected tumor identified by imaging or biopsy, diagnostic workup of nodal metastases, histological evidence, or specific staging, prognostic, or therapeutic decisions.
Testing modalities that do not meet coverage criteria lack sufficient published scientific literature confirming that they are required and beneficial for diagnosing or treating an individual's illness. This exclusion includes salivary biomarkers, HPV genotyping, gene expression profiling, biomarker panels incorporating genetic and nongenetic factors, and HPV detection from an oropharyngeal swab when used to screen for, detect, or diagnose oral cancer. The coverage criteria for establishing HPV tumor status are separate and apply only to the specified eligible cancer presentations and testing methods.